Xeris Biopharma (XERS) Expected to Announce Earnings on Thursday

Key Points

• Xeris Biopharma is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of ($0.03) per share and revenue of $64.58 million.
• Shares of Xeris Biopharma have seen a 1.7% increase, reaching a price of $5.18, with a market cap of $809.27 million.
• Insider Kevin Mcculloch purchased 25,000 shares at an average price of $4.38, increasing his ownership and highlighting insider confidence in the company.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Xeris Biopharma to post earnings of ($0.03) per share and revenue of $64.58 million for the quarter. Xeris Biopharma has set its FY 2025 guidance at EPS.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Trading Up 1.7%

Shares of NASDAQ XERS traded up $0.09 during trading on Friday, reaching $5.18. 616,563 shares of the company traded hands, compared to its average volume of 2,406,861. The firm's fifty day simple moving average is $4.83 and its 200 day simple moving average is $4.46. The stock has a market cap of $809.27 million, a P/E ratio of -17.15 and a beta of 0.66. Xeris Biopharma has a 12-month low of $2.10 and a 12-month high of $6.07.

Insider Transactions at Xeris Biopharma

In other news, insider Kevin Mcculloch bought 25,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares in the company, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.47% of the stock is currently owned by insiders.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Xeris Biopharma during the first quarter worth $96,000. Caxton Associates LLP purchased a new stake in shares of Xeris Biopharma during the first quarter worth $170,000. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the period. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after acquiring an additional 369,420 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock worth $461,000 after acquiring an additional 3,594 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on XERS shares. Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer boosted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.